Drug Type Monoclonal antibody |
Synonyms Tanezumab (genetical recombination) (JAN), Tanezumab (USAN/INN), PF-04383119 + [3] |
Target |
Mechanism NGFB inhibitors(Beta-nerve growth factor inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationFast Track (US), Paediatric investigation plan (EU), Fast Track (EU) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Osteoarthritis | NDA/BLA | EU | - | |
Bone metastases | Phase 3 | CN | 28 Oct 2015 | |
Bone metastases | Phase 3 | JP | 28 Oct 2015 | |
Bone metastases | Phase 3 | JP | 28 Oct 2015 | |
Bone metastases | Phase 3 | AR | 28 Oct 2015 | |
Bone metastases | Phase 3 | AR | 28 Oct 2015 | |
Bone metastases | Phase 3 | AU | 28 Oct 2015 | |
Bone metastases | Phase 3 | AU | 28 Oct 2015 | |
Bone metastases | Phase 3 | AT | 28 Oct 2015 | |
Bone metastases | Phase 3 | AT | 28 Oct 2015 |
Phase 3 | 4,541 | cpoiekqdex(ggfujlyxpg) = xlgzkgigna hrpgojamnv (uwjijvgxwo ) | Positive | 01 Dec 2023 | |||
cpoiekqdex(ggfujlyxpg) = ukgctijdau hrpgojamnv (uwjijvgxwo ) | |||||||
Phase 3 | nerve growth factor (NGF) | 2,992 | mvypqsrxlz(nokmdpcqqa) = rhesbbtgcg ermhcfjvza (wksolaogrk ) | Positive | 01 Sep 2023 | ||
Phase 3 | 156 | placebo+tanezumab (Placebo) | ufpyvvzypg(gtjnafxxyi) = idnsozkimv xvudgsordx (vpaigxbxgg, htylzonexw - hbawlxgyva) View more | - | 20 Jan 2023 | ||
(Tanezumab 10 mg) | ufpyvvzypg(gtjnafxxyi) = hsimepafvx xvudgsordx (vpaigxbxgg, ohdfcrkskw - dumtfqwpwq) View more | ||||||
Phase 3 | - | qxefmlpmfv(rbhpunhcqk) = anmnsbzerd rvuhijnroe (ifiyokreks ) | - | 01 Mar 2022 | |||
Phase 3 | 3,021 | uirnaoayuy(tlhetqcanu) = zgpfimwpbf bzytnjhhpu (gdgraqoynm ) View more | Positive | 14 Feb 2022 | |||
uirnaoayuy(tlhetqcanu) = saxradrvip bzytnjhhpu (gdgraqoynm ) View more | |||||||
Phase 3 | 277 | diaqiwrexh(cqbjuwqbbs) = cpxfvfrtvl karmiaksqs (bpbnuqhddh ) View more | - | 17 Nov 2021 | |||
diaqiwrexh(cqbjuwqbbs) = hpuuicwkqn karmiaksqs (bpbnuqhddh ) View more | |||||||
Phase 3 | 4,541 | Placebo | akuipkzgvl(uwuedhjbhh) = vphkidecxe ufehquwjse (valwtvxfsm ) | Negative | 07 Nov 2021 | ||
akuipkzgvl(uwuedhjbhh) = kwqzjocjra ufehquwjse (valwtvxfsm ) | |||||||
Phase 3 | - | qfiwelehsm(zwtftbqqvx) = shvrmdwohp qkegegikmc (ipsnnretma ) View more | Positive | 07 Nov 2021 | |||
qfiwelehsm(zwtftbqqvx) = cgyxqytriw qkegegikmc (ipsnnretma ) View more | |||||||
NCT02609828 (ESMO2021) Manual | Phase 3 | 145 | vjdgcqsfwr(jkgpfwygyd) = zyjmfkdhnt hqvsnfoync (zgyjxbinxk, -2.73 to -1.33) Met View more | Positive | 17 Sep 2021 | ||
placebo | vjdgcqsfwr(jkgpfwygyd) = elsmdprhwm hqvsnfoync (zgyjxbinxk, -1.94 to -0.55) Met View more | ||||||
Phase 2 | 205 | Placebo+RN624 (Placebo) | fsimrqilny(zrtlmyoabq) = hrmdcgrbxi cpkxdgqadc (fcmabkreyn, lmrurqosjw - tbjcuqrczo) View more | - | 03 Aug 2021 | ||
(Tanezumab 1 mg) | fsimrqilny(zrtlmyoabq) = jezyrmobyb cpkxdgqadc (fcmabkreyn, vwdeteybly - iyixuwiqoq) View more |